The inaugural project for the Neurotechnology Division addresses the unmet need for better non-opioid therapies for chronic pain in women. This project, which led to a patent filing and a proposal submission, furthers our mission to leverage state-of-the-art technologies for the benefit of human health.
Anacapa’s new Neurotechnology Division was launched in 2019. This launch included:
- hiring a Chief Scientific Officer (Dr. Songer)
- incorporating the company
- filing a patent
- completing the 6 registrations required for NIH (National Institute of Health) submission
- submitting a 5-year, $8M proposal to NIH